Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (111-120 of 167) with videos related to

Pageof 17
Sort By:
Cancers|September 28, 2023
Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung AdenocarcinomasAndrea Dell'Amore, Alessandro Bonis, Luca Melan, et al.
Clinical Lung Cancer|August 1, 2020
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS StudyDiego Cortinovis, Federica Grosso, Luciano Carlucci, et al.
British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.
Diagnostics (Basel, Switzerland)|October 1, 2020
A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) PatientsFrancesco Cortiula, Giulia Pasello, Alessandro Follador, et al.
Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.
Journal of Personalized Medicine|April 27, 2024
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology ReportGiulio Rossi, Luisella Righi, Francesca Barbisan, et al.
JCO Oncology Practice|April 7, 2021
Non-Small-Cell Lung Cancer: Real-World Cost Consequence AnalysisAlessandra Buja, Giulia Pasello, Giuseppe De Luca, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Karim Rihawi, Francesca Mazzoni, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Therapeutic Advances in Medical Oncology|August 1, 2020
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)Francesco Gelsomino, Giuseppe Lamberti, Marcello Tiseo, et al.
Pageof 17

Showing results (111-120 of 167) with videos related to

Sort By:
Pageof 17
Cancers|September 28, 2023
Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung AdenocarcinomasAndrea Dell'Amore, Alessandro Bonis, Luca Melan, et al.
Clinical Lung Cancer|August 1, 2020
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS StudyDiego Cortinovis, Federica Grosso, Luciano Carlucci, et al.
British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.
Diagnostics (Basel, Switzerland)|October 1, 2020
A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) PatientsFrancesco Cortiula, Giulia Pasello, Alessandro Follador, et al.
Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.
Journal of Personalized Medicine|April 27, 2024
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology ReportGiulio Rossi, Luisella Righi, Francesca Barbisan, et al.
JCO Oncology Practice|April 7, 2021
Non-Small-Cell Lung Cancer: Real-World Cost Consequence AnalysisAlessandra Buja, Giulia Pasello, Giuseppe De Luca, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Karim Rihawi, Francesca Mazzoni, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Therapeutic Advances in Medical Oncology|August 1, 2020
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)Francesco Gelsomino, Giuseppe Lamberti, Marcello Tiseo, et al.
Pageof 17